Rights issue in InDex Pharmaceuticals Holding AB (SE) — SEK 533 million

Carnegie acted as joint global co-ordinator in the SEK 533 million rights issue in InDex Pharmaceuticals. InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.
February 2021.